getting the word out

Looks like CXS has been invited to the

"BIO Announces Initial Companies Selected to Present at the Twelfth Annual BIO CEO & Investor Conference
by EDITOR on JANUARY 5, 2010

The Biotechnology Industry Organization (BIO) today announced the first 100 companies selected to present at the Twelfth Annual BIO CEO & Investor Conference. Presenting companies were selected through a
rigorous screening process and were evaluated based on several criteria,
including their potential to deliver on near-term clinical catalysts and
accomplishments across major therapeutic markets and areas of unmet
medical need.
Selected companies are also distinguished by significant opportunities for value
creation with near-term clinical, regulatory and corporate catalysts
that will continue to foster the growth of our industry in the new
decade.
Over 120 presenting companies will be selected and posted on the
conference website on a rolling basis. To view the latest list, please
visit http://ceo.bio.org.
This years presenting companies were chosen using metrics developed by
BIOs internal Industry Analysis team and were further vetted by an
Advisory Committee, comprised of members from top-tier investment firms
and CEOs from leading biotech companies:
Alger Boyer; Managing Director, Equities Group, Rodman & Renshaw,
LLC
Benjamin R. Bowen, Ph.D.; Managing Director, Investment Banking, Rodman
& Renshaw, LLC
Ron Cohen, M.D.; President & CEO, Acorda Therapeutics
J. Donald deBethizy, Ph.D.; President & CEO, Targacept
David Farhadi, M.D.; Vice President, Senior Analyst/Co-Portfolio
Manager, Fred Alger Management, Inc.
Howard Furst, M.D.; Partner, Deerfield Management
Cory W. Kasimov; Vice President , J.P Morgan
David Kroin; Managing Director, Great Point Partners, LLC
Kelly Lisbakken; Vice President, Investment Banking, Wedbush
PacGrow Life Sciences
Mark Schoenebaum, M.D.; Managing Director & Senior Biotechnology
Analyst, Deutsche Bank AG
Chris Swindle; Managing Director, Wedbush PacGrow Life Sciences
The BIO CEO & Investor Conference will showcase companies representing
the industrys most promising investment opportunities with late-stage
clinical pipelines, well-established business strategies or strong M&A
and partnering potential, said Alan Eisenberg, executive vice
president, Emerging Companies & Business Development at BIO. Selected
companies are also distinguished by significant opportunities for value
creation with near-term clinical, regulatory and corporate catalysts
that will continue to foster the growth of our industry in the new
decade.
Now in its twelfth year, the BIO CEO & Investor Conference is the
largest independent investor conference for the life sciences industry
focused on publicly-traded biotechnology companies. The meeting provides
a neutral forum where institutional investors, industry analysts, and
senior executives from leading global pharmaceutical and biotechnology
companies have the opportunity to shape the future investment landscape
of the biotechnology industry.
This years meeting will feature issue-oriented plenary sessions,
company presentations and educational sessions focused on business
trends and hot therapeutic areas in life sciences. Access to top
investors and industry executives will also be powered by BIO One-on-One
Partnering, BIOs interactive online system that allows you to
intelligently search, contact and schedule one-on-one meetings.
To learn more about the BIO CEO & Investor Conference, including
registration and program information, please visit http://ceo.bio.org.
Registration is complimentary for qualified investors and credentialed
members of the media."


To see the full list of invites see the link

http://aggregator.in/2010/bio-announces-initial-companies-selected-to-present-at-the-twelfth-annual-bio%C2%B0-ceo-investor-conference-6406/